Inflammatory diseases are a major burden on humanity, despite recent successes with
biopharmaceuticals. Lack of responsiveness and resistance to these drugs, delivery …

Abstract Learning Objectives After completing this course, the reader will be able to:
Differentiate between ligand-dependent and ligand-independent human epidermal growth …

Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

Gefitinib is active and well tolerated in patients with advanced non-small cell lung cancer
(NSCLC); however, its role in patients with brain metastases has not been clearly defined …

Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Phase I studies established a fixed daily oral dose of 150 …

▪ Abstract The clinical application of tyrosine kinase inhibitors for cancer treatment
represents a therapeutic breakthrough. The rationale for developing these compounds rests …

The CME activity for this article is forthcoming. Access and take the CME test online and
receive 1 hour of AMA PRA category 1 credit at CME. TheOncologist. com Gefitinib (Iressa®; …

Lung cancer is the most common cause of cancer death. The vast majority of patients
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …

Purpose: To determine if tumor regression following treatment with gefitinib correlates with
the presence of sensitizing mutations in epidermal growth factor receptor (EGFR). Patients …

The treatment of lung cancer has changed rapidly over the last few years and now more
than ever a multi-disciplinary approach is vital to patient care. Surgical resection remains the …